PDCD1 and neoplasm: We also identified synergic contributions of PD1 blockade to the known anti–angiogenic and tumour pro–apoptotic effects of cabozantinib, lessening the angiogenic microenvironment through immune modulation and modulating T-cell cytotoxicity.